These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26843348)

  • 1. Letter: effectiveness of golimumab to induce remission in outpatient ulcerative colitis in Italy.
    Tursi A; Della Valle N; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Aliment Pharmacol Ther; 2016 Mar; 43(5):657-8. PubMed ID: 26843348
    [No Abstract]   [Full Text] [Related]  

  • 2. Golimumab for the treatment of ulcerative colitis.
    Flamant M; Paul S; Roblin X
    Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
    Renna S; Mocciaro F; Ventimiglia M; Orlando R; Macaluso FS; Cappello M; Fries W; Mendolaro M; Privitera AC; Ferracane C; Pisana V; Magnano A; Pluchino D; Inserra G; Scarpulla G; Garufi S; Carroccio A; Siringo S; Di Mitri R; Cottone M; Orlando A
    Dig Liver Dis; 2018 Dec; 50(12):1292-1298. PubMed ID: 30007516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous golimumab therapy for ulcerative colitis.
    Lowe AW; Moseley RH
    Gastroenterology; 2014 Jan; 146(1):1-2. PubMed ID: 24501748
    [No Abstract]   [Full Text] [Related]  

  • 7. Golimumab: clinical update on its use for ulcerative colitis.
    Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
    Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
    Pugliese D; Privitera G; Rogai F; Variola A; Viola A; Laterza L; Privitera AC; Allocca M; Bossa F; Cappello M; Daperno M; Lorenzon G; Mazzuoli S; Principi M; Sablich R; Moser L; Ferronato A; Traini S; Tapete G; Bodini G; Di Girolamo M; Grossi L; Mocci G; Ricci C; Saibeni S; Festa S; Spagnuolo R; Cortelezzi CC; Mocciaro F; Rizzello F; Armuzzi A;
    United European Gastroenterol J; 2021 Feb; 9(1):102-109. PubMed ID: 33203342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence.
    Olivera P; Danese S; Pouillon L; Bonovas S; Peyrin-Biroulet L
    Dig Liver Dis; 2019 Mar; 51(3):327-334. PubMed ID: 30555013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Detrez I; Gils A
    J Crohns Colitis; 2017 Jan; 11(1):1-2. PubMed ID: 27481879
    [No Abstract]   [Full Text] [Related]  

  • 13. IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs.
    Danese S
    Nat Rev Gastroenterol Hepatol; 2013 Sep; 10(9):511-2. PubMed ID: 23897288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease.
    Roblin X; Paul S
    Aliment Pharmacol Ther; 2015 Jul; 42(2):240. PubMed ID: 26081687
    [No Abstract]   [Full Text] [Related]  

  • 15. Initial experience with golimumab in clinical practice for ulcerative colitis.
    Castro-Laria L; Argüelles-Arias F; García-Sánchez V; Benítez JM; Fernández-Pérez R; Trapero-Fernández AM; Gallardo-Sánchez F; Pallarés-Manrique H; Gómez-García M; Cabello-Tapia MJ; Talavera-Fabuel A; Bejarano-García A; Leo-Carnerero E; Hernández-Martínez Á; Caunedo-Álvarez Á; Herrerías-Gutiérrez JM
    Rev Esp Enferm Dig; 2016 Mar; 108(3):129-32. PubMed ID: 26786341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
    J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
    Toor K; Druyts E; Jansen JP; Thorlund K
    J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis.
    Tursi A; Allegretta L; Della Valle N; Hadad Y; Penna A; Pranzo G; Ricciardelli C; Paiano P; Picchio M
    Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):e61-e63. PubMed ID: 27297910
    [No Abstract]   [Full Text] [Related]  

  • 19. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on anti-TNF agents in ulcerative colitis.
    Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
    Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.